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Entourage: Visualizing Relationships between Biological Pathways
using Contextual Subsets
Alexander Lex, Christian Partl, Denis Kalkofen, Marc Streit, Samuel Gratzl,
Anne Mai Wassermann, Dieter Schmalstieg, and Hanspeter Pﬁster
Fig. 1. Entourage showing the Glioma pathway in detail and contextual information of multiple related pathways.
Abstract—Biological pathway maps are highly relevant tools for many tasks in molecular biology. They reduce the complexity of the
overall biological network by partitioning it into smaller manageable parts. While this reduction of complexity is their biggest strength,
it is, at the same time, their biggest weakness. By removing what is deemed not important for the primary function of the pathway,
biologists lose the ability to follow and understand cross-talks between pathways. Considering these cross-talks is, however, critical in
many analysis scenarios, such as judging effects of drugs. In this paper we introduce Entourage, a novel visualization technique that
provides contextual information lost due to the artiﬁcial partitioning of the biological network, but at the same time limits the presented
information to what is relevant to the analyst’s task. We use one pathway map as the focus of an analysis and allow a larger set of
contextual pathways. For these context pathways we only show the contextual subsets, i.e., the parts of the graph that are relevant to a
selection. Entourage suggests related pathways based on similarities and highlights parts of a pathway that are interesting in terms of
mapped experimental data. We visualize interdependencies between pathways using stubs of visual links, which we found effective
yet not obtrusive. By combining this approach with visualization of experimental data, we can provide domain experts with a highly
valuable tool. We demonstrate the utility of Entourage with case studies conducted with a biochemist who researches the effects of
drugs on pathways. We show that the technique is well suited to investigate interdependencies between pathways and to analyze,
understand, and predict the effect that drugs have on different cell types.
Index Terms—Pathway visualization, biological networks, subsets, graphs, biomolecular data
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1 INTRODUCTION
All living organisms can be considered as highly complex networks of
biomolecules (genes, gene products, and metabolites) and biochemical
reactions. It is the sum of tightly controlled and regulated interactions
between these components that determines an organism’s form and
function. In the study of biological networks, the series of actions
among biomolecules that lead to speciﬁc biological effects are com-
monly described as biological pathways. In other words, a pathway
is a meaningful subset of biomolecules and reactions whose interplay
fulﬁlls a function in a cell or organism. Some pathways describe
metabolic processes, e.g., the production of the amino acid tyrosine
(Tyrosine metabolism pathway), whereas other pathways highlight the
processes involved in a disease, such as the Glioma pathway, which
describes the molecular mechanisms dysregulated in brain cancers.This creation of subsets is, however, largely artiﬁcial, with the goal
of reducing the complexity so that it can easily be comprehended by
humans. While this approach in general is very successful it also has
its drawbacks. By focusing only on those components that are imme-
diately relevant to a biological process under study, other interaction
partners that might only become relevant under speciﬁc circumstances,
e.g., the treatment of a disease, are left out. For example, cancer is often
caused by defects in multiple genes and pathways. In these cases, the
identiﬁcation of genes that are shared between dysregulated pathways
is of high relevance because their products constitute prime targets for
modulation by compounds, i.e., changing their activity using drugs.
Furthermore, many drugs do not only bind to one target but exhibit ac-
tivity against multiple gene products. For example, Dovitinib (TKI258)
is a drug that targets, among others, the products of the genes EGFR,
FGFR1, and PDGFRbeta, which are well-known proto-onco genes
(normal genes that if mutated or highly expressed can potentially cause
cancer). In these cases, the study of all affected genes and pathways in
a common reference framework is highly desirable to better understand
the drug’s effect on the tumor cell. Moreover, some gene products are
relevant in different cellular processes and drugs interfering with their
function could potentially have multiple therapeutic indications. If a
drug has already been approved because it has proven clinical safety, it
is attractive to study the role of the drug’s target in all possible pathways
to ﬁnd other disease implications and novel therapeutic uses of the drug.
Lastly, it is important to consider the effects of a drug on all possible
pathways to avoid undesirable side effects that result from unwanted
modulations of the biological network.
In this paper we present Entourage, a visualization technique that
allows analysts to conduct the kind of inter-pathway analysis required
to answer such questions. By visualizing not only a single pathway,
but including contextually relevant pathways, Entourage allows re-
searchers to analyze the effects that modulations in one pathway might
have on other interconnected processes. The primary challenge of
doing so is dealing with scale. Individual pathway maps often contain
several dozens, sometimes hundreds of nodes in addition to rich meta-
information and are designed for full-screen, one-at-a-time viewing.
While several approaches for integrating multiple of those pathway
maps exists (e.g., [29, 19, 12]) we ﬁnd that none are particularly suc-
cessful in showing the relevant information at the right level of detail.
Ourﬁrstcontributionthereforeisthecontextualsubsetsconcept
that addresses this problem. By showing a small number of pathways
(one or two) as focus pathways in detail, while showing contextual
subsets of a set of related pathways, we enable analysts to see the
details of the most important pathway, while keeping them informed
about the interdependencies to other pathways.
Our second contribution is Entourage, which employs the con-
textualsubsetsconcept, addressespracticalissuesinitsrealization,
and introduces several domain speciﬁc visual encodings. In partic-
ular, we show how we determine related pathways and how we indicate
potentially relevant content. Furthermore we describe our technique
to visualize relationships between pathways and our approach to ef-
ﬁciently manage screen space. Moreover, we show how Entourage
integrates advanced visualization techniques for analyzing large quanti-
ties of genomic and pharmacological data.
We demonstrate the utility of the contextual subset concept and
the Entourage system in case studies on KEGG [13] pathways and
the public Cancer Cell Line Encyclopedia (CCLE) [4] dataset. The
CCLE dataset contains rich genetic proﬁling data for more than 500
cell lines (cultures of cells) in addition to pharmacological data that
records responses of each of these cell lines to a set of 24 approved
cancer drugs or drug candidates, which are referred to interchangeably
in the following as drugs or compounds. We show that Entourage is
indeed a highly valuable tool to (a) understand drug sensitivities of
cell lines in light of their different genomic proﬁles and, consequently,
distinct dysregulated pathways, and (b) explain different therapeutic
indications for a single compound.
2 DOMAIN GOALS AND BIOLOGICAL BACKGROUND
While the analysis of relationships between multiple pathways is an
important task in many application scenarios, our development of the
Entourage technique was driven by three domain goals in drug dis-
covery. We have been in close collaboration with an early stage drug
discovery research group from a large pharmaceutical company over a
period of several months, which included several meetings with larger
groups of researchers and weekly meetings with one of their domain ex-
perts. In the following we describe their analysis goals and the datasets
required to achieve these goals.
Understand a drug’s mechanism of action and drug sensitivities of
cell lines. The target of established drugs is typically known. In many
cases, such drugs inhibit one or multiple gene products. However, there
are ﬂuctuations on how cell lines with distinct genomic proﬁles respond
to the drugs [4]. Finding out why, for example, some cancer cells are
killed by the drugs while others survive is one objective.
Judge side effects and safety of drugs. Although drugs are often de-
signed to modulate only one particular biological pathway, their action
on the cell and the organism as a whole must be considered in their de-
velopment to better assess their safety. Being able to analyze cross-talk
between pathways can help in judging the potential risks associated
with a compound early on in the drug development process [32].
Identify potential for repositioning of drugs. Two alternative routes
are usually taken in drug discovery: (1) developing new chemical
entities and (2) ﬁnding new uses for already existing or previously
failed drugs that have shown an adequate clinical safety proﬁle [2]. The
second route is usually more effective as such drugs can be approved
quicker. As more and more knowledge about biological interactions
and reﬁned pathway maps become available, it is quite possible that
existing drugs can be repurposed for a broader spectrum of therapeutic
indications. Inter-pathway analysis can help to identify potential new
therapeutic uses for approved drugs.
The data to be analyzed in these tasks can be classiﬁed into three
categories: pathway data, and two forms of experimental data: genomic
and pharmacologic proﬁling data. We have already introduced pathway
data, and will now brieﬂy explain the experimental data.
Genomic proﬁling data refers to datasets that measure the activity
or structural variation of genes. An example of genomic activity is
gene expression (or mRNA expression), which indicates how much of
a functional gene product, such as a protein, is produced. Changes
in gene activity can cause pathway dysregulation and a diseased state.
One reason for a change in gene activity can be a structural variation.
Structural variations occur on different scales. They can affect only
a single base pair in the DNA or modify a whole chromosome. Two
common forms of structural variation data are copy-number variation
data, which records large scale duplications or deletions of genes, and
mutation data, which captures smaller changes within an individual
gene. Structural variation can result in changed activity or even loss
of function. For example, a mutation in the gene PTEN results in
uncontrolled signaling in a pathway promoting cell survival, which can
lead to tumor growth [5]. The joint analysis of pathways and genomic
experimental data makes it possible to identify such effects.
Pharmacologic proﬁling data essentially measures how cells react to
compound exposure. A common measure is the half maximal inhibitory
concentration (IC50), which reports the concentration at which a drug
achieves 50% inhibition, e.g., the drug concentration that is required
to kill half of the treated tumor cells. The lower the concentration, the
more effective is the drug and the more sensitive is the cell line under
study to the drug treatment.
Pharmacologic and genomic proﬁling data are commonly jointly
analyzed to, for example, identify reasons for the differential response
that cell lines show to drug treatment. Integrating pathways into such
an analysis can make it much more targeted, since it allows analysts
to focus on the processes inﬂuenced by the compound and to explore
related processes. Currently, several distinct tools are used for this
analysis. Entourage is the ﬁrst system to combine the different data
types into one integrated interactive visualization.3 ANALYSIS TASKS
All of the domain goals described in the previous section have pathway
analysis as pivotal parts of them. In this section we break down these
domain goals into generalizable analysis tasks. We have elicited these
tasks through interviews and feedback sessions with our collaborators.
We classify the detailed tasks into two categories, the Pathway Intercon-
nectivity tasks and the Pathway-Experimental Data Linking tasks. Note
that both of those tasks are among the most critical requirements in
pathway analysis [26] and are considered open problems in biological
network analysis [1].
The Pathway Interconnectivity tasks deal with ﬁnding pathways
related to each other and analyzing the relationships between pathways.
The analysis tasks are:
Find related pathways. While an initial pathway is typically known
for the stated goals, it is important to easily ﬁnd related pathways, as
cross-talk and other interdependencies are more likely between highly
related pathways. We consider two pathways as related when they
either share one or multiple genes (nodes), have an edge crossing from
one pathway to the other, and/or if one is contained or referenced in the
other.
Identify high-level relationships of pathways. When related path-
ways are found, it is also important to see how they are related. For ex-
ample, it is interesting to see whether the same sub-process is contained
in both pathways, or whether one pathway is contained or referenced
within the other pathway.
Identify the role of a gene in multiple pathways. Identifying the role
of a gene in other pathways is important to determine the different
cellular processes that a gene is involved in, which, for example, is
valuable knowledge when assessing the suitability of a gene as a drug
target.
Find path intersections. As a change in gene activity, e.g., caused
through a mutation or modulation by a drug, can inﬂuence the activity
of subsequent genes in a path, it is important to not only look for the
role of the originally altered gene but also to explore the role of genes
that might be inﬂuenced by it. This can be done by exploring the
relationships of the nodes downstream of the original gene, i.e., by
ﬁnding pathways that intersect the path of a changed gene.
The Pathway-Experimental Data Linking tasks are equally important
to achieve the goals stated above, as only experimental data can give
insight into the effects a change, either naturally occurring or introduced
by drug treatment, has on the whole cell or organism. We have in
the past conducted an extensive task and requirement analysis for
jointly analyzing pathways and experimental data [24]. The ﬁve elicited
requirements (dealing with large scale data, dealing with heterogeneous
data, resolving multi-mappings, following pathway layout constraints,
and enabling topology-based and attribute-based tasks at the same
time) equally hold for our domain goals. In addition, we identiﬁed the
following, more speciﬁc, analysis tasks:
Identify subsets of pathways that warrant detailed investigation.
As we have discussed in previous work, trying to show all experimental
data on top of pathways is futile [24]. Consequently, analysts must be
able to easily identify subsets of pathways (i.e., genes or paths) that
warrant a closer look at the mapped experimental data.
Identify relationships between cell line responses to drug treat-
ment and genomic data. Our collaborators would like to ﬁnd out
why certain cell lines react differently to the same compound treatment.
These differences typically have genetic causes. Joint analysis of all the
aforementioned data types can reveal the reasons for such differential
behavior. This knowledge could in turn be used for targeted therapy,
i.e., the identiﬁcation of patients that are most likely to respond to a
speciﬁc drug treatment.
4 RELATED WORK
There are two major classes of visualizations that show interconnections
between pathways. The ﬁrst of these avoids sub-division by showing
the overall network as a whole. The second shows multiple path-
ways and visualizes relationships between them.
One-Network Approaches. As an example of the ﬁrst class,
KEGG [13] provides a high-level overview of the metabolic network
(the KEGG Atlas) and lets analysts drill down into individual pathways.
Other tools, like iPath [33] or Pathway Projector [16] use the same un-
derlying data but improve the interaction with the atlas. While the orig-
inal KEGG Atlas and iPath both use hyperlinks to replace the network
overview with pathway maps on demand, Pathway Projector embeds
node information directly on the all-encompassing map, thereby rely-
ing wholly on zooming and panning for navigation. Pathway Projector
differs from the other two also in respect to how it represents gene
nodes. The KEGG Atlas and iPath both represent genes and embedded
pathways only as edges between the metabolites (the intermediate prod-
ucts of the metabolism), while the Pathway Projector actually shows
nodes for genes, enzymes, and metabolites, which allows for direct
mapping of experimental data.
All of these techniques show an incredibly large amount of data on a
single screen. For example, the KEGG Atlas for E. coli, a comparatively
simple organism, summarizes 1,365 genes, 1,813 enzymes, and 1,572
metabolites. In order to handle all this data, these techniques rely
on selecting a focus, either by zooming and panning, or by changing
into a different view altogether. This makes it very hard to identify
interrelations to parts of the network outside of the currently visible
area. All of these examples rely on a static layout, making features such
as the layout lens [31] that pull connected nodes into focus, impossible.
Multiple Pathway Maps Approaches. The approach of show-
ing multiple pathways and visualizing relationships among them is
taken in earlier versions of the Caleydo system, for example, in the
Jukebox [29] and the Bucket [19] techniques. Both of them arrange
multiple pathways in a 2.5D layout, while one of the pathways serves
as focus. Visual links are used to connect related items on demand. As
both techniques use thumbnails for context pathways, labels or even
individual nodes are hard to see. Also, none of the techniques can show
more than one relationship at a time.
Similar to the Caleydo techniques, Jusuﬁ et al. extended the Vanted
system to show multiple pathways as thumbnails [12]. They use navi-
gation glyphs that show how individual nodes are connected to other
pathways. A glyph has one petal for each possible link to other pathway
groups, where the length of the petal encodes whether there is a link to
a pathway group or not. These petals can be used to navigate to other
pathways. The system, however, does not show any relationships on a
node level.
Hybrid Approaches. VisANT [11] takes a hybrid approach by
showing a larger network as a set of meta-nodes which can be un-
collapsed to reveal the underlying nodes and their cross-pathway con-
nections. In the visualization community such meta-nodes are typically
referred to as super nodes and are supported by a wide range of general
purpose graph visualization frameworks such as Tulip [3] or CGV [31].
The concept of meta- or super nodes is signiﬁcantly different from that
of our contextual subsets as the nodes are not smart with respect to the
context. A super node is either collapsed or not, whereas contextual
subsets can show the elements that are contextually relevant while
hiding the others.
The approach by Klukas and Schreiber [15] also employs super
nodes. It uses a force-directed graph layout of abstracted pathway nodes
and their relationships. Each abstract pathway node can interactively
be expanded to show all the nodes of the corresponding pathway in
detail. These nodes are arranged using the KEGG layout. They show all
cross-pathway connections of individual nodes for multiple pathways
at the same time. While this approach is reasonable for a limited set of
pathways, the adding of more pathways continuously introduces clutter
and reduces node size.
Rohrschneider et al. [25] use a similar approach in terms of showing
multiple pathways at the same time, but use a grid-based automatic
layout for the overall metabolic network. Their navigation approach
is of particular interest, because they use the table-lens metaphor to
switch between pathway super nodes and detailed renderings of the
pathway. However, as with all super node approaches, the nodes are
either expanded or collapsed but do not allow a context-based preview.Consequently, the technique also can only provide detail and context
for a very small set of pathways simultaneously.
General Subset Techniques Our approach is also related to
subset visualization techniques such as VisBricks [18] or Portals [23,
10]. VisBricks partition numerical datasets into subsets and show each
subset with the visualization technique most suitable for the contained
data and task. Portals are local regions within a visualization that show
a different view on the area they cover. Olston and Woodruff employ
portals to show data overlayed on maps [23], while the Hadlak et al.
in-situ visualization uses portals (also) for graphs [10]. None of these
techniques however, use any form of semantic context. Notice that we
use the term portal to refer to shared nodes between pathways and that
this usage is unrelated to Olston and Woodruff’s term.
Visualizing Experimental Data in Pathways We use the en-
Route technique [24] to visualize experimental data. enRoute uses
path extraction and a separate linked view, which we integrated into
Entourage. In contrast to Entourage, enRoute is strictly limited to a
single pathway and has no notion of ﬁnding or presenting related or
multiple pathways. Entourage and enRoute are complementary: the
former addresses the problems of large and disjoint networks, while
the latter makes it possible to visualize many node attributes.
5 VISUALIZING PATHWAY RELATIONSHIPS
Enabling the Pathway Interconnectivity tasks requires a joint analysis
of multiple pathways. Current techniques, however, lack the ﬂexibility
required for exploring interdependencies across pathway boundaries.
The main problem one must address is scale. Current approaches
either cannot show individual nodes sufﬁciently large or cannot show
relationships between multiple pathways. We developed contextual
subsets to remedy this issue.
Figure 2 illustrates the difference between a traditional multiple
pathway analysis and the contextual subsets method. The traditional
approach depicted in Figure 2(a) shows all nodes for all pathways.
The pathways in this example share several nodes. We refer to such
shared nodes as portals as they allow us to jump from one pathway
to another. Figure 2(b) illustrates the same set of pathways using the
contextual subsets technique. Instead of showing all pathways in detail,
we distinguish between focus pathways, shown at full scale (PW 1 in
Figure 2(b)), and context pathways, which are smaller and show only a
contextually relevant subset of their graph (PW 2 and 3 in Figure 2(b)).
What is contextually relevant is driven by a user-selected focus node (A,
purple in Figure 2(b)). The context pathways only show limited subsets
of their network that also contain node A. In the example shown in
Figure 2(b), the most important path is shown for each occurrence of
the focus node, while other branches are only indicated, as is evident in
Pathway 2.
(a) Traditional Multi-Pathway Visualization
(b) Pathways as Contextual Subsets
Fig. 2. Comparison of a traditional multi-pathway approach and contex-
tual subsets. (a) All pathways are shown at the same scale competing for
display space. (b) The contextual subset technique showing one focus
pathway (PW 1) and two context pathways (PW 2, PW 3). The context
pathways only show paths that contain the focus node A.
This simple yet effective principle makes use of an observation:
analysts do want to see all the details of one pathway map (their fo-
cus pathway), but do not need to see all the intricate details of other
potentially involved processes (the context pathways) to judge interde-
pendencies to their focus pathway. Entourage utilizes the observation
that the focus of attention shifts serially to optimize the visible content
to what is currently relevant to the analyst. The challenge we have
to address is the continuous change of attention, the adaption of the
analysis focus in the process of an exploration. Entourage employs
a series of visual encodings and interaction techniques to make these
changes as convenient and transparent as possible.
5.1 Overview
Figure 3 shows Entoruage’s main components. The focus pathway
takes up the majority of the space, while the context pathways are
shown at the side. In this example E2F was selected as the focus node
and the context pathways show their paths related to this node. Details
on how context paths are selected are explained in Section 5.2, as are
our methods to ﬁnd relevant pathways.
Changes in focus are driven by user selections. However, choosing
a meaningful focus is not always easy. Sometimes analysts will need
to understand high-level relationships of pathways before they can set
a sensible focus. Visualization is ideally suited to convey such high
level relationships. Relationships between pathways are largely driven
by portals as they connect two pathways. Showing portals and where
they link to is therefore the most important aspect of showing high-
level relationships between pathways. Figure 3 shows our approach for
visualizing portals. We use a combination of stubs, which are shown
for all portals at the same time, and visual links, i.e., visible edges,
which are shown on request. These visual encodings efﬁciently convey
high-level relationships between pathways and enable an analyst to set
good focus points. Our visual encodings for showing relationships are
explained in Section 5.3.
Finally, we need to address how to efﬁciently manage display space,
as multiple focus and context elements compete for the limited screen
real estate. We use an intelligent arrangement of pathways as well as
multiple levels of detail for context pathways to optimize the display
space, which are described in Section 5.4.
5.2 Determining Context Paths and Pathways
As discussed before, the contextual subsets concept is based on showing
contextual information for a user-chosen focus, i.e., a focus node of a
pathway. Which context information is eventually displayed depends
on two factors: which paths in a pathway contain a focus node and
which pathways are considered in the ﬁrst place.
Determining Context Paths Context paths are selected by search-
ing the graph for occurrences of the focus node or for immediately
related nodes. Related nodes are, for example, nodes belonging to the
same gene family. As it is common in nature that several distinct genes
can fulﬁll the same role, albeit often with varying efﬁciency, pathway
maps use both, a single label for the whole family or individual label
for each of the family members. We consider these multi-mappings
in our choices of relevant paths. This is the reason why occasionally
differently labeled nodes are connected in Entourage.
Paths can either be unambiguous, as is the case in Pathway 3 of
Figure 2(b), or contain branches, as in Pathway 2. If a path contains
branches we automatically determine the branch that is likely to be
most interesting by calculating the most variable branch in terms of the
underlying experimental data. We do so by calculating the standard
deviation across all experiments for each of the mapped datasets for
every possible branch and choosing the branch that exhibits the highest
deviation. As discussed in previous work [24], we preserve as much of
the topology in the vicinity of paths as possible. Incoming and outgoing
branches are collapsed into abstract nodes to save space, but can be
extended to full-size nodes and switched-in to replace the main branch
on demand. We decided against more complex attempts of linearizing
larger portions of the network and including branches and cycles [22],
to make the paths easy to understand for the analyst. Furthermore,
we limit the length of automatically determined paths to what ﬁtsPortals with Stubs Focus Pathway
Window Stub
Focus Node
Context 
Pathways
Portal Links
Matching
Focus Nodes
Fig. 3. The major components of Entourage. The focus pathway shows all details while the context pathways only show what is relevant in the
context of the focus node. The insets at the top show how we indicate connections between pathways.
conveniently in the available space constraints, but give analysts the
ability to extend the paths manually.
Determining Pathways Entourage shows paths only for manually
selected pathways but suggests pathways that are relevant for a current
focus node. Figure 1 shows a list of pathways on the left side. This list
contains all pathways that contain the currently selected focus node, or
a node of the same gene family. The pathways in the list are ranked by
their similarity to the current focus pathway. We calculate a similarity
score for each pathway by computing the number of nodes shared with
the focus pathway and normalize it by its size. The score is shown as a
bar next to the pathway name. To quickly determine which pathways
have already been added to the workspace we mark loaded pathways
using a dark gray background. In some situations analysts are interested
in pathways that are generally similar to a selected pathway, without
choosing a focus node. We use a similar algorithm to calculate scores
of pathways in this scenario.
An alternative to the automatic, similarity based list is an alphabetic
list which can be searched using keywords or regular expressions. This
is especially helpful to ﬁnd an entry point of an analysis. Finally, since
pathway maps often embed related pathways, we enable the adding
of such pathways to the workspace by clicking on embedded pathway
nodes. The Melanoma focus pathway shown in Figure 3, for example,
contains six embedded pathways indicating that these pathways play
an important role in the context of the focus pathway. One of them
(Cell cycle) is also a current context pathway, which is indicated by its
purple border.
5.3 Visualizing Connections
To ﬁnd path intersections and to enable the identify high-level relation-
ships task we need to visually communicate which portal nodes connect
two pathways. This requires visual encodings to (a) convey that a node
(either in a focus or in a context pathway) is a portal and to (b) tell the
analyst to which other portals it can be connected to.
Since related pathways often contain a substantial quantity of portal
nodes, obvious approaches, such as color-coding or drawing visible
edges, may easily fail. Even though objective (a) could be addressed by
using a color-based highlighting of portal nodes, objective (b) would
potentially require assigning many different colors to a single node.
Visual links (i.e., visible edges), on the other hand, can connect a
node to many others, but can result in signiﬁcant clutter, given the
many nodes and the dense layout of pathway maps, even if they were
intelligently routed [28]. Therefore, we have chosen to primarily use
stubs to encode relationships between nodes. Stubs were shown to be
effective for indicating a connection without cluttering the display [7].
Figure 3 illustrates our stubs implementation. The two insets at the
top show them in detail. For each pair of related portal nodes we
render a pair of stubs pointing at each other. The direction of a stub
thus indicates the location of its target. We attach the stubs to the
side of the node closest to the target and we quickly let them fade
while they are converging to a point. We also show portals only with
respect to the “active” pathway, i.e., stubs only point to and from the
pathway on which the mouse pointer rests. This reduces the set of
portals, minimizing clutter and ambiguities while showing all relevant
connections.
As context pathways only show a subset of nodes, potential portals
might not be displayed. Nevertheless, we also want to communicate
the presence of hidden portals. To achieve this, we show that a pathway
has a relationship to the active pathway through one or multiple hidden
portals by placing a stub on its window’s title bar, as shown in Figure 3
(labeled window stub).
As is evident from the ﬁgures in this paper, stubs are excellent at
indicating connections between many portal nodes without introducing
a high amount of visual clutter. However, they can be ambiguous at
times, especially when the angle between two stubs attached to the
same node is small. To resolve potential ambiguities, we show the exact
connections out of a portal node by using visual links when the mouse
hovers over the portal (labeled portal links in Figure 3).Medium
High Low
Fig. 4. The three different levels of detail of a context pathway. The
highest level shows context paths plus a thumbnail of the overall pathway.
Notice that the thumbnail also highlights the context paths. The medium
level only shows the context paths, and the lowest level reduces the
pathway to its title.
Notice that while relationships between portals are generally indi-
cated by gray stubs, the recurring focus nodes in the different pathways
are emphasized by using purple stubs or links. This combination of
gray and purple stubs and on-demand visual links results in a clean visu-
alization showing cross-connections between pathways in a minimally
obtrusive way. These visual encodings also work well for comparing
two focus pathways. What remains is to discuss how we can make
good use of the limited screen space.
5.4 View Management
Using contextual subsets signiﬁcantly reduces the number of elements
that need to be displayed yet preserves the relevant context. Neverthe-
less it is prudent to make good use of the available screen space. Here
we describe how we optimize the arrangement, size, and amount of
data shown in the various pathways under analysis.
When optimizing a layout for pathway analysis, one is confronted
with a range of partially conﬂicting goals. The ﬁrst and most obvious
goal is to maximize the amount of relevant content shown. This often
conﬂicts with the goal to ensure legibility of all elements. Following
the contextual subsets concept, we always use at least one focus path-
way, for which we comply with the legibility goal, thus limiting the
remaining space for contextual information. To deal with the varying
amounts of space, we promote and demote pathways to various levels
of detail and optimize the pathway layout.
Levels of Detail Our approach to efﬁciently layout pathways re-
quires us to change their size. We achieve this by introducing three
levels of detail for context pathways: high, medium, and low, which
are illustrated in Figure 4. The thumbnail used in the highest level
is typically large enough to convey a sense of the overall topology of
the pathway. In order to aid orientation, we highlight the route of the
context path(s) in the thumbnail, as shown in the inset of Figure 4.
However, we consider this topological information less relevant than
the actual context, which is why we omit the thumbnail if space is
limited. In situations where there is not enough space to show any
context paths, we resort to showing only the pathway titles. While this
is not ideal, it is better than removing the pathway, since (a) it can be
conveniently brought back into focus or any other level of detail and
(b) it still indicates whether there is context information to be shown.
Promotion or demotion of pathways between these levels of detail and
the focus can be triggered manually but is also done automatically.
Automatic actions can be disabled for individual pathways. This also
makes a high-level comparison of two focus-pathways possible.
Layout Optimization We decided to use a rigid column-based
layout to arrange pathways as opposed to a free layout, since matrix-like
layouts are more space efﬁcient when it comes to layouting rectangular
shaped objects like pathway maps. Also, a column-based layout is
well suited to reﬂect the history of the analysis process by sorting the
pathways by age. Entourage can accommodate as many columns as are
reasonable for a given screen resolution, but always enforces at least
one context column as well as a minimum width for a column.
Our initial implementation followed the goals outlined above, always
aiming to maximize the visible context information while ensuring leg-
ibility. Early feedback, however, triggered the realization that another
factor is essential: layout stability. We observed that our collaborators
were irritated by layout changes, even though they were animated. As
a consequence we added the goal of minimizing layout changes. We
also found that changing the size of a particular pathway is much less
irritating than changing its position, either within or between columns.
Consequently, our layout algorithm now prohibits position changes un-
less the focus pathway is exchanged, but permits resizing and switching
between levels of detail of context pathways.
Within a context column, we maximize the vertical space between
individual pathway windows. While this might not be as aesthetically
pleasing as stacking them on top of each other, this strategy serves a
purpose: It helps to avoid ambiguities of stubs pointing to the pathways
by increasing the angle between stubs.
To fulﬁll our goal of maximizing the amount of relevant content
displayed we promote and demote pathways intelligently. Automatic
demotion of pathways is triggered when the horizontal or vertical
display space is insufﬁcient for displaying all elements at a reasonable
size, while automatic promotion is triggered as space becomes available.
An important decision in this regard is which pathways to demote or
promote. This primarily depends on the causes of the space change. For
example, if the vertical space is exceeded by the pathways in a context
column, only pathways within that column have to be considered for
demotion. Incontrast, ifthereistoolittlehorizontalspace, thedemotion
of any pathway can potentially free up space.
To ultimately decide which of the pathways to demote or promote,
we use three attributes of various priorities. The highest priority is
given to pathways that contain a user-selected path (see Section 6).
The second-highest priority is given to pathways that currently contain
context paths. Finally, pathway “age” is considered as the lowest
priority, where “young” pathways, i.e., those that were recently in
focus, are given priority. We calculate a ranking of the candidate
pathways based on these attributes and eventually demote the pathway
with the lowest priority.
Taken together, our layout considerations guarantee a stable and
predictable management of many pathways.
The techniques and encodings discussed in this section allow ana-
lysts to take a detailed look at one pathway while always keeping an
eye open for cross-connections to other pathways. By showing only
the information relevant to the current analysis, the important parts of
the data can be shown at full scale. We thus provide an analyst with the
necessary tools to address the Pathway Interconnectivity tasks.
6 EXPERIMENTAL DATA ANALYSIS
So far we have focused on how to visualize relationships between
pathways considering only the pathways and the underlying network.
In this section we will introduce (a) how experimental data can be
leveraged to select interesting pathways and cross-connections in the
ﬁrst place and (b) how to visualize experimental data in the context of
pathways and pharmacologic data. We will thereby address the two
Pathway-Experimental Data Linking tasks.
The ﬁrst of these tasks is to identify subsets of pathways that warrant
detailed investigation based on experimental data. To accomplish this
task, we need to provide information on which nodes are interesting in
terms of the mapped experimental data. The most common approach
to supplement pathways with experimental data is to color-code the
nodes [20]. Other approaches include small bars, line plots, etc. For
a comprehensive analysis refer to the review by Gehlenborg et al. [8].
All of these approaches aim at encoding experimental data on top of the
pathways. However, such attempts are futile when dealing with large
and heterogeneous datasets, but are helpful for single, homogeneous
datasets [24]. Consequently, we make it possible to map individual(a) (b)
Fig. 5. Path selection and experimental data mapping in pathways. The
path highlighted in orange (a) is extracted and presented in a top-down
layout (b). The node color in this example encodes the average copy
number of mapped samples, while the red bars indicate the standard
deviation. The exclamation marks indicate that the mapped experimental
data varies considerably. The color of the exclamation marks and the
standard deviation bars encodes the dataset in which the variation occurs.
In this example blue marks signal variation in mutation and green marks
show variation in mRNA expression data. Notice that we show cancer
data in a cancer pathway, so it is not surprising that a high number of
genes are mutated.
datasets by color coding the nodes, if desired (see Figure 5), but by de-
fault take a different approach: We point analysts to parts of a pathway
that are either interesting for exploring the underlying experimental
data or that are relevant to consider in other pathways. We do so by
calculating the standard deviation of experimental data associated with
each gene. If this deviation is higher than a threshold, we show an
exclamation mark, as shown in Figure 5. The color of the exclamation
mark encodes the dataset where the deviation was observed, which is
also used in the data mapping view (see Figure 1). If multiple datasets
show a large deviation, we encode only the largest. We chose a glyph
since it nicely supplements the color-coding of nodes we use for show-
ing average values of a single, selected dataset. This feature addresses
the aforementioned task well, as typically variability in the data is of
most interest.
For visualization of the actual underlying experimental data we
employ the enRoute technique [24], which is part of the Caleydo frame-
work. enRoute requires analysts to select a path in the network for
which detailed experimental data is shown. Selected paths are high-
lighted using Bubble Sets [6]. Figure 5(a) shows a simple example of
a selected path, the resulting extracted path is shown in Figure 5(b).
Entourage always keeps track of the selected path in the selected path
view, shown in Figure 1 on the right. By default, only the path is shown,
but this view can be expanded to show enRoute, as demonstrated in
Figure 7. Notice, that the enRoute view can also be shown full-screen,
thereby occluding the pathways but giving more space to the experi-
mental data analysis. Which data and which stratiﬁcations (groupings)
of experiments are shown is driven by analyst choices made in the data
mapping view shown in Figure 1 at the bottom.
While the original enRoute technique can only be used for paths
in a single pathway, Entourage is ideally suited to select paths across
pathways, as is shown in Figure 1. Notice that pathway boundaries are
included in the path representation. We chose not to extend the bubble
sets across pathways but instead use the visual links we also use for
portals, as the connecting portal nodes are in fact the same node.
Finally, to address the identify relationships between cell line re-
sponses to drug treatment and genomic data task, we extended enRoute
to show contextual data that is not associated with genes. Such data is
shown above the gene-associated data and uses the same ordering of
samples. Figure 6 shows the compound sensitivity of ovary CCLE can-
cer cell lines to the drug AEW541 on top of the expression (on the left)
and copy number values (on the right) associated with the RAF gene
family (BRAF, ARAF, RAF1). Here, low bars indicate high sensitivity,
i.e., low IC50 values. Notice that the samples are sorted with respect to
their sensitivity to the compound, which is a simple yet effective way
to search for relationships between genomic and pharmacologic data.
This visual encoding can successfully address the task of associating
cell line responses and genomic data. Moreover, since, for the small set
of compounds the targeted processes and genes are known, it is easy
to identify paths where interesting relationships between genomic and
pharmacological data occur.
Fig. 6. Juxtaposition of pharmacological (on top) and genomic data. The
pharamcological data captures the sensitivity of cell lines to drugs. The
genomic data shown is mRNA expression (green, on the left) and copy
number variation data (red, on the right). Orange bars are highlighted.
Notice that the samples are sorted by the magnitude of their responses
to the drug AEW541.
7 IMPLEMENTATION AND SCALABILITY
Entourage is part of the open source Caleydo Biomolecular Data Vi-
sualization Framework1. Caleydo is implemented in Java and uses
JOGL [9] for rendering. Entourage will be a part of the next Caleydo
release. We use an adapted version of the freely available implementa-
tion of Bubble Sets [17] for highlighting selected paths. Our Entourage
implementation works with pathway maps from the KEGG [13] and
WikiPathways [14] databases (see supplementary material for exam-
ples). Although we use the layouts provided by these databases in our
current implementation, our technique is not limited to those and can
equally be applied to automatically generated pathway layouts.
Depending on the size of the current focus pathway, Entourage can
display up to ten pathways simultaneously, where one pathway is the
focus pathway while the other pathways are at least in “medium” level
of detail on a full HD notebook display (see supplementary material for
examples). On larger, higher resolution screens, this number increases.
The space for pathways can be increased by hiding currently unused
support views (the data mapping, pathway list, and path views shown in
Figure 1). Feedback from our collaborators indicates that this number
of simultaneously explorable pathways is sufﬁcient in all but the rarest
cases and superior compared to other systems. We believe that our
visual encodings are also suitable to point at interesting relationships
outside an analyst’s primary ﬁeld of view, making it suitable for the
increasingly large displays that are becoming commonplace. On con-
ventional displays we typically limit the number of focus pathways
to one in order to guarantee readability. This number, however, can
be temporarily increased if detail about the structural relationship of
pathways should be shown.
8 CASE STUDIES
Entourage was developed in a user-centered design process including
weekly meetings between the visualization developers and multiple
domain experts. As a result of these meetings we have established
the 3 domain goals and the 6 analysis tasks. We deployed various
iterations of Entourage and our primary contact, a biochemist, who
is also an author of this paper, used Entourage over a period of four
weeks. During this period we were in constant contact with her and
reﬁned various aspects of the system. The case studies presented here
report on her observations. Prior to the deployment of Entourage the
team was using conventional pathway tools and had to resolve any ques-
tions concerning pathway relationships manually. For visualization
of experimental data they mainly relied on tools like TIBCO Spot-
ﬁre [30], whereas interactions between biomolecules were analyzed
with network visualization tools like Cytoscape [27] or the KEGG web
interface. Hence, Entourage allowed them to integrate two analysis
steps that were previously carried out separately into one single task.
In the following we describe case studies for the domain goals con-
cerning drugs’ mechanisms of action and drug repositioning, which we
found representative for demonstrating Entourage’s functionality. The
case studies either describe a novel observation or clearly demonstrate
how a known effect can be rationalized with Entourage.
1http://caleydo.orgUnder-expressed
Over-expressed
Not sensitive
Fig. 7. The ErbB signaling pathway (the focus pathway) is a target of the drugs Lapatinib and Erlotinib that are used for cancer treatment. As shown
in the pathway list on the left that results from a query for similar pathways, the ErbB signaling pathway is related to many cancer pathways. A
signaling cascade from ErbB2 to Ras is selected. The integrated enRoute view shows copy number and mRNA expression data for breast cancer
cell lines. The sensitivity of the different cell lines to Lapatinib and Erlotinib is reported at the top. For the shown cell lines, increased copy numbers
of ErB2 (high red bars in the ErbB2 row) result in over-expression of this gene (high blue bars). Furthermore, there is a strong relation between
ErbB2 over-expression and sensitivity to Lapatinib (high blue bars for gene over-expression in the ErbB2 row coincide with low bars in the Lapatinib
row). This means that Lapatinib is effective if ErbB2 is highly expressed. There are, however, two exceptions - the highlighted cell lines (gold and
orange), for which an under-expression in Ras downstream in the pathway is observed, likely causing Lapatinib to be ineffective in these cases.
While this observation was made for breast cancer tissue, exploring the related context pathways by setting the focus node to Ras reveals that
the same signaling cascade (i.e., path) is also contained in the non-small cell lung cancer pathway. Thus, it would be interesting to explore the
transferability of the observed resistance pattern to this tissue type.
8.1 Relating Genomic Features to Compound Sensitivity
To explain different compound sensitivities of cell lines, our collabora-
tor used the previously introduced CCLE dataset. This dataset contains
data on the inhibitory effects of 24 drugs against roughly 500 cell lines
from different cancer tissues and genomic data. Ideally, a drug com-
pletely inhibits the growth of these cell lines at minimal concentrations.
First, she wanted to investigate factors that sensitize cell lines to the
drugs Lapatinib and Erlotinib that inhibit members of the ErbB gene
family and are used in cancer treatment. The ErbB family is a family of
epidermal growth factor receptors that are known to play an important
role in tumor growth. The drug Lapatinib is a dual inhibitor of EGFR
and ErbB2, while Erlotinib is a known inhibitor of only EGFR, all
of which belong to the aforementioned family. Due to its immediate
relevance, the expert started by loading the ErbB signaling pathway
into Entourage. By searching for related pathways she found several
cancer-speciﬁc pathway maps. The pathways Glioma and Non-small
cell lung cancer ranked among the top on the list (see Figure 7). She
commented that this indicates that the ErbB signaling pathway is a key
player in these diseases. For the ErbB pathway map, our collaboration
partner was interested in the experimental data for the genes in the path
that leads from ErbB receptors to Myc, a gene known to regulate cell
growth. She also noticed that ErbB2 was highlighted with a red excla-
mation mark indicating high variance in the copy number data. She thus
selected the genes of this path for an in-depth analysis. She then looked
at this path’s gene expression data in the embedded enRoute view and
combined it with sensitivities to Erlotinib and Lapatinib. For the analy-
sis, cell lines were grouped by their tissue of origin (e.g., breast, ovary,
liver, etc.) and sorted by sensitivity to Lapatinib. Her ﬁrst observation,
when looking at the experimental data, was that the two drugs displayed
inhibitory activities across cell lines from many different tissues. The
cell lines from lung, breast and three other tissues were in general most
responsive. The set of cell lines that were responsive to Erlotinib and
Lapatinib largely overlapped, although Lapatinib showed a broader
spectrum of activity than Erlotinib. She found a strong co-occurrence
between ErbB2 mRNA over-expression and sensitivity to Lapatinib in
lung and breast cancer cell lines, a trend that was less apparent or not
observed at all for other responsive cell lines.
She then chose to focus on cell lines from breast and also investigated
copy number variation for these cell lines. For most breast cancer cell
lines that over-expressed ErbB2, high copy numbers of this gene were
found, i.e., the increased expression could generally be traced back to
an increased copy number. Interestingly, only two breast cancer cell
lines that showed strong over-expression of ErbB2 did not respond to
Lapatinib treatment. The columns of these two cell lines are highlighted
gold and orange in Figure 7. She then tried to ﬁnd the cause for this
effect and examined the expression of downstream genes in the pathway.
She found that for these two cell lines, the gene Ras was strongly under-
expressed (also shown in Figure 7).
It is straightforward to assume that this under-expression further
down the path counteracts the over-activation of the pathway by in-
creased ErbB2 expression, explaining the resistance to Lapatinib treat-
ment that reduces the effects of ErbB2 expression. Our collaborator
stated that this highlights the importance of being able to analyze ge-
nomic data in a pathway context because compound sensitivities can
often only be explained by the interplay of multiple genomic features.
Based on this observation she started to investigate whether other
cancer-related pathways contain the same signaling cascade, i.e., path.
She selected Ras as the focus node of her analysis, which revealed
several other pathways that contain the same ErbB signaling cascade.
Figure 7 shows an example where it is obvious, due to the many parallel
stubs that the cascade is indeed identical. Our collaborator commented
that it would interesting to investigate in the future whether a simi-
lar gene expression pattern in these cancer types would also entail
resistance to Lapatinib.
8.2 Rationalizing Successful Drug Repositioning
Graft-versus-host disease (GVHD) is frequently observed after tissue
or organ transplantation and is caused by immune cells that originate
from the donor and were transplanted with the tissue. These immune
cells perceive tissue of the recipient as foreign and attack it, thereby
causing damage. The Graft-versus-host disease pathway identiﬁes
TNF-alpha, a gene involved in inﬂammation, as an important playerFig. 8. TNF-alpha (the focus node) was originally explored as a target for the Graft-Versus-Host Disease (GVHD, top-right pathway). However,
when tested in clinical trials, TNF-alpha inhibiting compounds were not effective against GVHD but could later be repositioned for the treatment of
Rheumatoid Arthritis (focus pathway). Entourage shows Rheumatoid Athritis as closely related to the GVHD pathway (see pathway list on the left).
Entourage also reveals seemingly contradictory roles of TNF-alpha. It is involved in cell death (Apoptosis) and also in cancer (i.e., uncontrolled cell
growth) through the MAPK signaling pathway.
in the disease. Accordingly, molecules counter-acting (inhibiting) the
effect of TNF-alpha have been evaluated for preventing GVHD in
transplantation patients, with no success. However, the roles of TNF-
alpha in the organism are manifold, as our collaborator was able to
demonstrate using Entourage, when she chose TNF-alpha as her focus
node, revealing all associated pathways. She found that one of the
highest scoring and therefore most similar pathway to the Graft-versus-
host disease map is the Rheumatoid arthritis pathway, shown as the
focus pathway in Figure 8. Indeed, as clinical safety for TNF-alpha
inhibitors had been proven in the initial trials for GVHD patients,
the molecules were revisited and tested for their efﬁcacy in patients
sufferingfromrheumatoidarthritis. Inthiscase, anti-TNFalphatherapy
showed the desired clinical effect and today TNF inhibitors are part
of the standard treatment of rheumatoid arthritis. The domain expert
pointed out that Entourage also ranks the Apoptosis, MAPK signaling,
and NF-kappa B signaling pathways, which explain the controversial
role of TNF-alpha in cancer. While the Apoptosis pathway shows the
process by which TNF-alpha leads to cell death, the other two pathways
point out how TNF-alpha contributes to cell survival. Accordingly, the
beneﬁt of TNF-alpha inhibitors in anti-cancer treatment remains an
open question and clinical trials are awaited to further explore the
potential use of these molecules in malignancies.
9 CONCLUSIONS AND FUTURE WORK
Analyzing relationships between pathways to accommodate analysis
scenarios such as accounting for pathway cross-talk, repurposing drugs,
and relating genomic features to drug sensitivity are challenging and to
date unsolved problems. Previous approaches have aimed to show all
considered pathways as a whole or even tried to represent the whole
network at the same time. We have argued that doing either is not
scalable and at the same time unnecessary. Our approach uses a strict
focus and context approach, where the focus as well as the relevant
context is presented at any given time. We use a combination of
carefully chosen visual encodings and analytical support to help experts
ﬁnd the important parts of their data.
Overall, our collaboration partners were excited about the analytical
capabilities of Entourage and mentioned that they perceived a signiﬁ-
cant improvement over their previous tool-chain. While, for example,
the KEGG interface could be used to conduct an analysis similar to the
one described in the second case study, doing so would be very tedious,
as KEGG provides no support for analyzing relationships of pathways.
They highly valued the ability to immediately see all relevant related
processes for a pathway and being able to compare them easily and to
see experimental data in the context of pathways.
We have demonstrated the utility of Entourage in two case studies
highly relevant for pharmacological research. These case studies re-
ﬂect current needs of pharmaceutical research, but we believe that our
technique is equally applicable in domains such as systems biology
or general molecular biology, as interconnections between pathways
inﬂuence virtually all domains involved with biomolecular data.
Moreover, we argue that the contextual subsets approach can be
applied to general graph analysis. It is conceivable that automatically
created clusters of a graph can be used instead of manually partitioned
pathways. We also believe that several other aspects presented in this pa-
per can be generalized to other visualization applications. In particular
our methods for visualizing relationships could be used for supplemen-
tary relationships in graphs, while our view management approach is
applicable to all techniques using ﬂexible multi-view setups.
In the future we aim to investigate how to represent compound data
and its inﬂuences on the biological network. For the CCLE data, visu-
alization of protein-compound interaction, for example, is irrelevant,
since the compounds covered by this dataset are few and well under-
stood. There are, however, similar datasets being created that contain
data for hundreds or even thousands of compounds, about which there
is only limited knowledge available. Early research in this area [21]
highlights the important role visualization can play in this domain.
Another potential future line of inquiry is that of comparative analy-
sis of multiple paths. Consider an example where two branches con-
verge into a single node. Current visualization techniques are either not
able to deal with the quantity of node attributes necessary to conduct a
sensible analysis or fail to represent the topology efﬁciently, opening
opportunities for interesting visualization research.
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